Mucormycosis Treatment Market Forecast, Trend Analysis and Competition Tracking - Global Market insights 2015 to 2031

Mucormycosis Treatment Introduction

Mucormycosis is also called zygomycosis or black fungus. It is a severe but rare angio-invasive infection caused by a group of fungi called mucormycetes. Spores of these ubiquitous fungi are inhaled and cause infection in the lungs, sinuses, which can also extend into the brain and eyes if not treated properly. Mucormycosis is non-contagious disease. It is not spread from 1 person to another.  Mucormycosis affects patients/people who are immunocompromised or patients already infected with other diseases. Mucormycosis is an aggressive and life-threatening infection—it requiring rapid diagnosis and early treatment. There is a greater risk of infection in diabetic patients, who have had treatment with higher doses or longer courses of steroids, suffering from cancer, HIV/AIDS patients, who have weak immune systems for other reasons, and recently many people with covid-19 have been diagnosed with mucormycosis.

Request Covid - 19 Impact

Mucormycosis Disease Burden Globally by Regions, 2020

Global Mucormycosis Treatment Market Revenue Outlook:

The global mucormycosis treatment market is valued at US$ 522 Mn in 2020 and is projected to register а САGR of 4.1% by 2031.

Nonetheless, various industry players in the global mucormycosis treatment markets are now increasing their focus towards the establishment of successful collaborations, acquisitions, and joint venture activities as a means to enhance their respective customer bases. In doing so, these players are also increasing their supply capabilities to meet customer requirements on a local and global scale. This factor, paired with promising industrialization prospects in developing economies of the Asia-Pacific region, such as China, India, Taiwan, Indonesia, etc., are expected to create massive business opportunities for key players over the forecast period.

COVID-19 Impact on Mucormycosis

Fungal infections including mucormycosis, aspergillosis and invasive candidiasis cases have been testified in patients with severe COVID-19 or those recovering from the disease and have been associated with severe illness and death. The prevention of COVID-19 associated mucormycosis continuously focuses on improving glycemic control in COVID-19 patients and monitors the use of systemic corticosteroids in treating severe cases. New guidelines for using systemic corticosteroids/other immunomodulation drugs for mild or moderate patients with COVID-19 are implemented. Health care facilities are strengthening their infection prevention and control (IPC) programs to prevent healthcare-associated outbreaks.

Mucormycosis Disease Burden in Different At-risk Population

Higher Prevalence of Fungal Infections is a Major Factor

The prevalence rate of fungal infection increases due to the growing elderly population and patients with low immune systems. This is another factor proliferating the growth of the target market over the forecast period.

• As per World Population Prospects 2019 report published by the UN, the number of people aged around 80 years old or above is projected to triple from 137 Million in 2017 to 425 Million by 2050. By the year 2100, this number is expected to increase to 909 Million, around seven times that of 2017.
• According to the UN, approximately 962 Mn people were 60 years old and above globally in 2017, comprising 13% of the global population. This number is projected to reach 1.4 Bn by 2030 and 2.1 Bn by 2050

Estimated Burden of Mucormycosis in Different Countries, 2020

Type of Mucormycosis and Some common symptoms

Source: WHO, 2021

Analyst Point on Mucormycosis Treatment Market

Among the types, the Rhizopus segment is expected to dominate the market. On the basis of treatment type, Amphotericin B therapy is projected to register a high market share. Amphotericin B therapy is the only approved antifungal therapy for mucormycosis is and is widely used in Europe as the standard of treatment. The Mucormycosis Treatment Market also requires comprehensive strategies to manage Acute Agitation and Aggression Treatment effectively, enhancing the overall patient experience.

Competitive Landscape

The landscape appears highly consolidated, with a major chunk of it being dominated by players.

• Abbott Laboratories
• Biocon Limited
• Cadila Pharmaceuticals Limited
• Novartis AG
• Hoffman La Roche
• Merck Sharp and Dohme
• Mylan Labs
• Bristol Myers Squibb
• Bayer AG
• Lonza Group
• Sanofi
• Johnson & Johnson
• Other Players

 Some notable developments in the market include:

• In May 2021, Five companies, namely; Emcure Pharmaceuticals, Natco Pharma, Gufic Biosciences, Alembic Pharmaceuticals and Lyca Pharmaceuticals, secured the new drug approval for manufacturing Amphotericin-B – mucormycosis drug in India
• In June 2021, Mankind Pharma launched Posaforce 100 – drug use to treat mucormycosis or black fungus disease. The drug is permitted by the Drugs Controller General of India (DCGI) and has proven its safer and effective drug for the treatment of mucormycosis.
• In May 2021, Bajaj Healthcare (BHL) launched Posaconazole API – a triazole antifungal agent indicated for treating Mucormycosis patients popularly known as Black Fungus in post-Covid complications. The drug will be commercially available from June 2021.
• In May 2021, Celon Laboratories launched Amphotericin B Emulsion, which is used for the treatment of Mucormycosis or Black Fungus.

Report Scope

• Forecast Period: 2022-2031
• Actual Year: 2021
• Historical Data Available for: 2015-2020

Key Regions Covered

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Segments Covered

Mucormycosis Treatment Market, By Type

• Rhizopus
• Rhizomucor
• Cunninghamella
• Apophysomyces
• Saksenaea
• Lichtheimia
• Mucor

Mucormycosis Treatment Market, By Diagnosis

• CT Scan
• MRI
• Tissue Biopsy

Mucormycosis Treatment Market, By Treatment Types

• Surgery
• Antifungal drugs
• Amphotericin B therapy
• Other Treatment Types

Mucormycosis Treatment Market, By End Users

• Hospitals
• Specialty Clinics
• Homecare
• Other End-Users